Abdul-Ghani M, et al. - In this study, experts sought to identify predictors for response to combination therapy with pioglitazone plus exenatide vs basal/bolus insulin therapy in T2DM patients who were poorly controlled on maximum/near-maximum doses of metformin plus a sulfonylurea. Findings revealed that the increment in 2-hour plasma C-peptide concentration above the fasting level provided a useful tool that identified poorly controlled T2DM patients who could achieve glycemic control without insulin therapy. Thereby, it could be used to individualize antihyperglycemic therapy in poorly controlled T2DM patients.